iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. iOnctura aims to improve current immune checkpoint therapies by developing novel drugs with potential best-in-class safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. Headquartered in Geneva, Switzerland, iOnctura was founded by M Ventures in June 2017.

Team Members
more about
Bauke Anninga
more about
Hakan Goker
Managing Director
Latest News Entry
IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program
  • Updated clinical data demonstrates a prolonged and sustained favorable safety profile for roginolisib (IOA-244)
  • Clinical data shows a comparable safety profile in both solid and hematologic malignancies
  • Clinical responses seen in both solid and hematologic malignancies
  • US FDA grants Orphan Drug Designation for IOA-244 in uveal melanoma
IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, announces today that it has been granted EUR17.5 million funding from the European Investment Council’s (EIC) Accelerator Program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of EUR2.5 million, and EUR15 million of equity investment.

IOnctura Initiates Phase Ib Pancreatic Cancer Trial Of Next-Generation Autotaxin Inhibitor IOA-289

iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, announces today the first patient has been dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.

iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289

iOnctura has preclinical data that shows its autotaxin inhibitor IOA-289 both inhibits pancreatic cells directly and inhibits the cancerpromoting activity of secreted factors from Cancer-Associated Fibroblasts (CAFS)

iOnctura To Present Preclinical Data On Its Clinical Stage Autotaxin Inhibitor, IOA-289, At AACR

iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research (AACR) taking place on April 8-13, 2022 in New Orleans, Louisiana.

iOnctura Expands its Clinical Advisory Board

iOnctura SA announces the addition of new members to its Clinical Advisory Board (CAB)

iOnctura selected for an oral presentation at 2019 AACR Annual Meetin

iOnctura SA announced today that its abstract (abstract # 1781) “Preclinical development of a novel, highly selective PI3Kδ inhibitor" has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019.

iOnctura Announces Appointment of Leading International Scientific Advisory Board

iOnctura SA, a recently founded late stage preclinical immuno-oncology company, announced today the formation of an international Scientific Advisory Board (SAB).

all related news
all portfolio news